SCHEMBL20952986

SCHEMBL20952986

C[C@@H](C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C)N(C)N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.68
NR3C1 P04150 12/20 0.55
AR P10275 6/20 0.55
CYP3A4 P08684 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 3/20 0.42
ESR1 P03372 3/20 0.42
CYP1A2 P05177 2/20 0.42
MAPK1 P28482 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 2/20 0.42
NR3C2 P08235 2/20 0.42
OPRM1 P35372 2/20 0.42
ESR2 Q92731 2/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
THPO P40225 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19286040 0.90 PGR (0.74) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL518768 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL3691258 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL17906556 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL13875056 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL13752884 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL6847373 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
Trimegestone SCHEMBL3155792 0.89 PGR (0.72) PGRNR3C1ARCYP3A4CYP2D6
SCHEMBL21231223 0.87 PGR (0.70) PGRNR3C1ARCYP3A4CYP2D6
SCHEMBL13875044 0.87 PGR (0.70) PGRNR3C1ARCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273263-B2 Pro-drug forming compounds EVESTRA, INC. (US) 2019-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273263-B2 Pro-drug forming compounds SUCNR1, FURIN, OGFR PGR 968/4885NR3C1 834/4885AR 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.